ECOG-ACRIN Cancer Research Group

Read more from our co-chairs on the importance of protecting public support for biomedical research: bit.ly/3IvxNQD #CancerResearch #ClinicalTrials

Thank you, @SARCtalks, @annieachee & team for updating #Sarcoma Centers Directory and creating brand new Advocacy Directory. Wow! Both great resources! sarctalks.org 🎙 Learn more: open.spotify.com/episode/42p3aE… #SarcomaAwareness #SARCTrials #SarcomaCommunity #Advocacy

Do you have high-risk #SmolderingMultipleMyeloma? If so, you may be eligible for EAA173/DETER-SMM, a #ClinicalTrial exploring new #SMM treatment approaches. For more information, click here: bit.ly/eaa173detersmm

#ClinicalTrial MM1OA-EA02, led by @jaltmanmd of @LurieCancer, aims to improve results for older adults with #AcuteMyeloidLeukemia (#AML). Learn more: bit.ly/ea3211-study #BloodCancer #leukemia

#ClinicalTrial EAF223/GABLE, led by Dr. Daniel Barboriak of @DukeRadiology, aims to help newly diagnosed patients with #Glioblastoma by testing a new treatment approach. Learn more: bit.ly/gable-trial

#FindingsFriday: Earlier this month, Dr. Amy Clark of @PennCancer & colleagues published the results of the BRACELET-01/PrE0113 #ClinicalTrial, testing the use of pelareorep for patients with metastatic, HR+ #BreastCancer. View the publication: bit.ly/4eWqo9g #BCSM

The EA5221/ACHIEVE clinical study is testing two different treatment approaches for older adults with advanced non-small cell #LungCancer. Learn more: bit.ly/ea5221-achieve #NSCLC #LCSM

#ClinicalTrial EA2222/PUMP, led by @michael_lidsky, is a randomized phase 3 study of #SystemicTherapy with or without hepatic arterial infusion for unresectable #Colorectal liver metastases. More here: bit.ly/ea2222-pump cc: @MichaelDAngeli2, @skmaithel, @AndreaCercek

Have you had surgery for squamous cell carcinoma of the head and neck (#HNSCC) that has come back? If so, you may be able to participate in this study of a potential new treatment. Learn more: bit.ly/ea3191-study #HeadAndNeckCancer #HNCA

.@immunosarc of @LurieCancer is leading EA7222, a randomized phase 3 trial of doxorubicin alone or in combination with pembrolizumab in patients with advanced UPS and related poorly differentiated #sarcomas. More here: bit.ly/EA7222 cc: @CureSarcoma

The EA3211 clinical study is now open to a broader population of patients! Patients with prior H&N radiation but new limited volume metastatic disease are now eligible. Learn more: bit.ly/ea3211-study #hncsm

Patients with newly diagnosed #SolidCancer may be eligible to participate in EAQ222CD/CostCOM, testing ways to reduce #FinancialHardship. Learn more about this research study here: bit.ly/EAQ222CD cc: @GelarehSadigh #FinancialToxicity

Do you have #ProstateCancer that has returned after prostatectomy? If so, you may be able to participate in this study of potential new treatment approaches. Learn more about the EA8191/INDICATE study: bit.ly/indicate-trial #pcsm #ProstateCancerAware

Great piece on the importance of maintaining, not cutting, federal funding of research. Millions of people have benefitted from the research supported by federal dollars.

Thanks @eaonc for highlighting the important mission to serve patients via innovative transformative research! Supporting research improves outcomes & saves lives! @Dr_AmerZeidan @VivekSubbiah @LeiDeng3 @DrOmarMian @spsutkaMD @montypal @mshadman @fredhutch @DimaDanai @FaltasLab

“Research that is stopped rarely gets going again”- @eaonc Protect public funding for biomedical research and investment in the cures of tomorrow👇🏽👇🏽👇🏽👇🏽

#ClinicalTrial EA4231, led by @MelanicjMD of @theNCI, is testing the effectiveness of a combination #TargetedTherapy for patients with aggressive B-cell #Lymphoma that has recurred or is resistant to treatment. For more info: bit.ly/EA4231 cc: @LLSusa, @lymphomahub

#Clinicaltrial EA8192 aims to find out if treatment with durvalumab and chemotherapy can improve outcomes for patients with high grade upper tract #urothelialcancer prior to nephroureterectomy. bit.ly/ea8192-trial #blcsm #bladdercancer cc: @JCensits, @PGrivasMDPhD

Do you have advanced #cancer that has become worse following treatment, or advanced cancer for which no standard treatment exists? If so, you may be able to join the #ComboMATCH #PrecisionMedicine study. Learn more: bit.ly/ComboMATCH

💯 % agree “discontinuing trials for which participants have already volunteered and are undergoing treatment does an enormous disservice to patients.”

Every unfinished trial means a lost chance for patients. Let’s keep moving, for the promise, for the people.